MiMedx: Developing and Distributing Placental Tissue Allografts Healthcare company, MiMedx Group, Inc. specializes in the processing of human placental tissues utilizing its patented and proprietary PURION process. The process produces allografts that maintain the tissue's biological properties and regulatory proteins. The company’s patented and proprietary processing method also employs aseptic processing techniques and terminal sterilization. MiMedx's products are used in wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. Some of the company's products include EpiFix, AmnioFix, EpiCord, AmnioCord, and AMNIOBURN, all of which have a semi-permeable protective barrier allograft. EpiFix is used for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. AmnioFix comprises dehydrated human amnion/chorion membrane for deployment in surgical recovery procedures. The company sells its products through direct sales force and independent sales agents, as well as independent distributors mainly in the United States. MiMedx Group, Inc. was incorporated in 2011 and has its headquarters in Marietta, Georgia. Their lead product is mdHACM, a micronized form of AMNIOFIX, supplied in powder form.
MiMedx Group's ticker is MDXG
The company's shares trade on the NASDAQ stock exchange
They are based in Marietta, Georgia
There are 501-1000 employees working at MiMedx Group
It is mimedx.com
MiMedx Group is in the Healthcare sector